Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

45P - Actionable mutations in matched liquid and tissue biopsy next-generation sequencing

Date

22 Mar 2024

Session

Poster Display session

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Elaine Ko

Citation

Annals of Oncology (2024) 9 (suppl_3): 1-53. 10.1016/esmoop/esmoop102569

Authors

E.Y. Ko1, C.H.L. Wong2, D. Shih1, J. Wong1, M.K.L. Chiu2, V.H.F. Lee2, A. El Helali2

Author affiliations

  • 1 HKU - The University of Hong Kong, Hong Kong/HK
  • 2 The University of Hong Kong - Li Ka Shing Faculty of Medicine, Hong Kong/HK

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 45P

Background

Sufficient tumour tissue at diagnosis and recurrence is often suboptimal for comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC). Furthermore, the turnaround time for tumour tissue CGP may impact timely treatment decision-making. However, liquid biopsies may compensate for this shortfall in terms of sample size and turnaround time. Given the limitations of liquid biopsies in detecting actionable alterations, due to insufficient circulating tumour DNA (ctDNA), we, therefore, investigated the accuracy and concordance of ctDNA CGP.

Methods

Patients were recruited as part of an ongoing multi-centre prospective Precision Oncology Programme in advanced NSCLC, in Hong Kong starting from July 2021. CGP was performed using FDA-approved Foundation One CDx and Foundation One Liquid CDx. The diagnostic accuracy of liquid biopsy was investigated by positive percentage agreement (PPA). The correlation of tumour mutational burden (TMB) was calculated with Pearson correlation.

Results

72 patients with matched liquid and tissue CGPs were analysed. In our cohort, the median age at biopsy was 69. 71% of the ctDNA samples had a tumour fraction score of <1%. Additionally, the average ctDNA TMB and tumour tissue TMB was 5.5 muts/Mb and 6.1 muts/Mb, respectively. 47% (n=35) of patients harboured ESCAT level I actionable mutations. The actionable mutations reported were: ALK fusions (n=1), BRAF V600E (n=2), EGFR L858R (n=17), EGFR Exon 19 deletion (n=13), KRAS G12C (n=1), and MET exon 14 splice site (n=1). The PPA of the reported actionable mutations in our paired cohort was 71%. Conversely, the correlation of TMB between liquid and tumour tissue was 0.56 with a PPA of 60%.

Conclusions

Importantly, our study highlights the potential of ctDNA in detecting clinically actionable mutations when tumour biopsies are unavailable. Conversely, ctDNA alone is not adequate in reporting TMB.

Legal entity responsible for the study

University of Hong Kong.

Funding

Roche Hong Kong Limited.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.